Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study of the Safety and Tolerability of Combining 20089 (Triamcinolone Acetonide Intravitreal Injection) When Used Adjunctively With Lucentis® 0.5 mg Intravitreal Injection in Subjects With Subfoveal Neovascular AMD

Next Previous
Search
Trial Profile

An Open-Label Study of the Safety and Tolerability of Combining 20089 (Triamcinolone Acetonide Intravitreal Injection) When Used Adjunctively With Lucentis® 0.5 mg Intravitreal Injection in Subjects With Subfoveal Neovascular AMD

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triamcinolone (Primary) ; Ranibizumab
  • Indications Age-related macular degeneration; Choroidal neovascularisation
  • Focus Adverse reactions

    • Most Recent Events

    • 28 Mar 2018 According to an EyePoint Pharmaceuticals media release, pSivida Corp. acquired Icon Bioscience and subsequently changed its name to EyePoint Pharmaceuticals.
    • 19 Oct 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 14 May 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top